Disease: Pulmonary mucormycosis

The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis

mycolabadmin

Mucormycosis is a dangerous fungal infection that kills many patients. Traditional tests like fungal culture are slow and often miss infections. This comprehensive study of 30 research papers shows that PCR testing is very effective at detecting this fungus, with different specimen types having different success rates. Blood tests were easiest to perform and worked well for screening high-risk patients, while fluid from the lungs was the most accurate.

Read More »

Pathogenic mucorales: Deciphering their cell wall polysaccharidome and immunostimulatory potential

mycolabadmin

Mucormycosis is a serious fungal infection that primarily affects people with weak immune systems and carries high mortality rates. Researchers studied three common mucormycosis-causing fungi to understand how their outer cell layers interact with the human immune system. They found that all three fungi trigger strong inflammatory responses, which may explain why the disease is so damaging. This research helps us better understand how these infections work and could lead to improved treatments or vaccines.

Read More »

Detection of Mucorales antigen in bronchoalveolar lavage samples using a newly developed lateral-flow device

mycolabadmin

Researchers developed and tested a new rapid test (TG11-LFD) for detecting mucormycosis, a dangerous fungal infection, using a simple device similar to a COVID rapid test. The test detects a specific protein marker released by Mucorales fungi in lung fluid samples. In testing with 62 clinical samples, the new test correctly identified about 77% of actual infections and was negative in about 76% of non-infected samples. This affordable, simple test could help doctors quickly diagnose mucormycosis and start life-saving treatment faster, especially in countries with limited laboratory resources.

Read More »

Epidemiology of mucormycosis in COVID-19 patients in northwest Iran: Rhizopus arrhizus as the predominant species

mycolabadmin

During the COVID-19 pandemic, some patients developed a severe fungal infection called mucormycosis alongside their coronavirus infection. This study found that 63 COVID-19 patients in Iran developed mucormycosis, which primarily affected the sinuses and brain. The researchers identified that a fungus called Rhizopus arrhizus caused most infections, and patients who received corticosteroids (used to treat severe COVID-19) had a higher risk, especially those who developed diabetes from the steroids.

Read More »

Brazilian task force for the management of mucormycosis

mycolabadmin

Mucormycosis is a rare but deadly fungal infection that has been increasingly reported in Brazil, especially during the COVID-19 pandemic. This Brazilian medical task force developed practical guidelines for diagnosing and treating this serious infection, which primarily affects people with uncontrolled diabetes or weakened immune systems. The key to survival is early diagnosis combined with aggressive surgery and specific antifungal medications, along with controlling blood sugar and immune system suppression.

Read More »

Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections

mycolabadmin

Researchers tested a new antifungal drug called SCY-247 in mice to treat serious fungal infections. The drug was given orally and showed strong effectiveness against common fungal infections caused by Candida and Rhizopus species, including strains resistant to current treatments. Higher doses of the drug produced better results, and the drug effectively concentrated in the organs most affected by fungal infections.

Read More »
Scroll to Top